Biomarkers
AssigneePsynova Neurotech Ltd.
InventorsSabine Bahn, Emanuel Schwarz
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of diagnosing or monitoring major depressive disorder using MMP-3 as a biomarker.
Claims26
1-24. (canceled)
A method of detecting altered MMP-3 expression in an individual suspected of suffering from major depressive disorder, comprising:
- i. obtaining a sample from the individual suspected of having major depressive disorder;
- ii. measuring the level of one or more biomarkers in the sample, wherein the one or more biomarkers comprise MMP-3;
- iii. comparing the level of the one or more biomarkers in the sample to the level of the one or more biomarkers measured in one or more reference samples obtained from control subjects that do not have major depressive disorder, and
- iv. detecting altered MMP-3 expression in the individual.
A method of treating an individual suspected of having major depressive disorder or predisposition thereto comprising:
- i. obtaining a first sample from an individual suspected of having major depressive disorder or predisposition thereto;
- ii. measuring the level of one or more biomarkers in the first sample, wherein the one or more biomarkers comprise MMP-3;
- iii. treating the individual for major depressive disorder;
- iv. obtaining a second sample from the individual;
- v. measuring the level of the one or more biomarkers in the second sample;
- vi. comparing the level of the one or more biomarkers in the first sample to the level of the one or more biomarkers measured in the second sample and;
- vii. altering the individual's treatment based on a difference between the level of the one or more biomarkers in the first sample to the level of the one or more biomarkers measured in the second sample.
The method of claim 39 wherein the one or more biomarkers measured comprises MMP-3, Prostate Specific Antigen Free, and Prolactin.
The method of claim 39 wherein the one or more biomarkers measured comprises MMP-3 and IL-1ra.
The method of claim 39 wherein the one or more biomarkers measured comprises MMP-3, Prostate Specific Antigen Free, von Willebrand Factor, EN-RAGE, Complement Factor H, Pancreatic Polypeptide, Resistin, Cancer Antigen 19.9, Follicle Stimulation Hormone (FSH), Prolactin, IL-1ra, IL-13, IL-7, Transferrin, IL-15, IL-16, IL-5, Apolipoprotein E, Alpha 2 Macroglobulin, Testosterone, Ferritin, Complement 3, IL-12p40, IL-3, IFN gamma, and C reactive protein.
Dependencies are inferred from the claim text.